Evaluation of haemostasis in children treated with valproic acid;Untersuchungen zur hämostase bei kindern unter valproatbehandlung

Hamostaseologie

Volumn 30, Issue SUPPL.1, 2010, Pages 132-137

  Schadlich D ^a   Friebel, D ^a   Schallner, J ^a   Gehrisch, S ^a   Siegert, G ^a   Kuhlisch, E ^a   Knofler R ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Children; Haemostasis; Valproic acid

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTICONVULSIVE AGENT; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 8; FIBRINOGEN; THROMBIN; VALPROIC ACID;

ARTICLE; BLOOD; BLOOD CLOTTING; CHILD; DRUG EFFECT; HEMOSTASIS; HUMAN; METABOLISM; PHYSIOLOGY; THROMBOCYTE AGGREGATION;

ADENOSINE TRIPHOSPHATE; ANTICONVULSANTS; BLOOD COAGULATION; CHILD; FACTOR VIII; FACTOR XIII; FIBRINOGEN; HEMOSTASIS; HUMANS; PLATELET AGGREGATION; THROMBIN; VALPROIC ACID;

EID: 79952108782     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Sandler RM, Bevan PC, Roberts GE. Interaction between sodium valproate and platelets: a further study. Br Med J 1979; 8: 1476.
2. Barr RD, Copeland SA, Stockwell ML, et al. Valproic acid and immune thrombocytopenia. Arch Dis Child 1982; 57: 681-684.
3. Bottom KS, Adams DM, Mann KP, Ware RE. Trilineage hematopoietic toxicity associated with valproic acid therapy. J Ped Hematol Oncol 1997; 19: 73-76.
4. Coulter DL, Wu H, Allen RJ. Valproic acid therapy in childhood therapy. JAMA 1980; 244: 785-788.
5. Gerstner T, Teich M, Bell N et al. Valproate-associated coagulopathies are frequent and variable in children. Epilepsia 2006; 47: 1136-1143.
6. Banerjea MC, Diener W, Kutschke G et al. Pro-and anticoagulatory factors under sodium valproatetherapy in children. Neuropediatrics 2002; 33: 215-220.
7. Kreuz W, Linde R, Funk M et al. Valproate therapy induces von Willebrand Disease Type I. Epilepsia 1992; 33: 178-184.
8. Sutor AH, Jesdinsky-Buscher C. Veränderungen der Hämostase bei Epilepsie-Behandlung mit Dipropylessigsäure - Erweiterte Untersuchung. Fortschr Med 1976; 94: 411-414.
9. Teich M, Longin E, Dempfle C-E, König S. Factor XIII deficiency associated with valproate treatment. Epilepsia 2004; 45: 187-189.
10. Von Voss H, Schulte-Berbühl R, Göbel U. Side effects of sodium valproate (sodium di-N-propylacetate) on malonyldialdehyde-production and other platelet function tests. Minerva Pediatrica 1978; 30: 1397-1404.
11. Verrotti A, Greco R, Matera V et al. Platelet count and function in children receiving sodium valproate. Elsevier Science 1999; 21: 611-614.
12. Cannizzaro E, Albisetti M, Wohlrab G, Schmugge M. Severe bleeding complications during antiepileptic treatment with valproic acid in children. Neuropediatrics 2007; 38: 42-45.
13. Chambers HG, Weinstein CH, Mubarak SJ, Wenger DR, Silva PD. The effect of valproic acid on blood loss in patients with cerebral palsy. J Pediat Orthopaed 1999; 19:792-800.
14. Mackay FJ, Wilton LV, Pearce GL et al. Safety of long-term lamotrigine in epilepsy. Epilepsia 1997; 38: 881-886.
15. Gidal B, Spencer N, Maly M et al. Valproate-mediated disturbances of hemostasis: Relationship to dose and plasma concentration. Neurology 1994; 44: 1418-1422.
16. Serdaroglu G, Tütüncüoglu S, Kavakli K, Tekglü H. Coagulation abnormalities and acquired von Willebrand' s Disease Type 1 in children receiving valproic acid. Neuropediatrics 2001; 33: 215-220.
17. Tanindi S, Akin R, Köseoglu V et al. The platelet aggregation in children with epilepsy receiving valproic acid. Elsevier Science 1996; 81: 471-476.
18. Eberl W, Budde U, Bentele K et al. Acquired von Willebrand syndrome as side effect of valproic acid therapy in children is rare. Hämostaseologie 2009; 29: 137-142.
19. Koenig S, Gerstner T, Keller A et al. High incidence of valproate-induced coagulation disorders in children receiving valproic acid: a prospective study. Blood Coagul Fibrinol 2008; 19: 375-382.
20. Zeitler P, Mingers AM. Gerinnungsveränderungen unter Valproattherapie. Pädiatrie hautnah 1996; 6: 476-478.